Piper Sandler initiated coverage of Allogene Therapeutics with an Overweight rating and $11 price target. The company’s pivot in January “sets it on the right course,” and its has “multiple shots on goal,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks
- Biotech Alert: Searches spiking for these stocks today
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
- Insider Trading: Allogene Therapeutics’ Insider Buys Shares Worth $5M
- Allogene Therapeutics price target lowered to $13 from $14 at Oppenheimer